Biotech Executives Fret Over Hassles And Uncertainties Of 'Right To Try'

At last week’s annual convention of the Biotechnology Innovation Organization (BIO) in Boston, FDA Commissioner Scott Gottlieb said during an on-stage interview that his agency has recently initiated a formal process for handling “Right to Try,” the law passed May 30 that allows terminally ill patients to use experimental drugs that have not yet been approved. But that’s little comfort to biotech CEOs, some of whom were overheard fretting about the new law—and the resources they would have to pour into handling a potential flood of requests from desperate patients.